Jumi Kim, Jung Il Chae, Hye Eun Kim, Min Ji Lee, Kyung Il Lee, Young Joo Jeon and Hyung Min Chung
Scientific Tracks Abstracts: J Cell Sci Ther
Integrin mediated-ECM (extracellular matrix) remo deling is one of the critical steps on vascular re-construction in specifi c pathological condition including ischemic vascular disease, because ECM provides a stable environment for cell growth, diff erentiation and migration. Aft er massive ischemic injury on blood vessels, cell transplantation using stem cell source into injured ischemic region can improve vascular function through cell engraft ment and forming neo-vessels on injured site. In this study, we derived vascular angiogenic progenitor cell population from hESC (hESC- VAPCs) and investigate their therapeutic eff ect and unique therapeutic mechanism on hindlimb ischemia disease model. As the result, hESC-VAPCs were retaining representative vascular characteristics in vitro and therapeutic eff ect on hindlimb ischemic model mouse. Blood perfusion rate on hESC- VAPCs transplanted group was signifi cantly improved than cord bold derived EPCs (CB-EPCs) and vehicle medium injection transplantation group. Furthermore, to fi ne out the therapeutic mechanism of hESC-VAPCs, we applied proteomic analysis tool between hESC-VAPCs and EPCs. Interestingly for this study, we could confi rm that main therapeutic behavior was caused by up-regulated participation of several ECM and integrin mediated signaling pathway in hESC-VAPCs. Together, these data suggest hESC-VAPCs could be a valuable novel cellular source for therapeutic treatment of vascular ischemic disease due to their participation of up-regulated several ECM molecules and integrin mediated pathway.